OmniaBio
San Diego, United States· Est.
AI‑enabled CDMO delivering scalable, cost‑effective cell and gene therapy manufacturing for oncology and immunology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑enabled CDMO delivering scalable, cost‑effective cell and gene therapy manufacturing for oncology and immunology.
OncologyImmunologyRegenerative Medicine
Technology Platform
AI‑driven closed‑unit bioreactor and robotics platform that automates cell culture, process development, and lentiviral vector production for scalable CGT manufacturing.
Opportunities
Rising demand for affordable, scalable cell and gene therapy manufacturing and the ability to leverage AI for cost reduction and faster time‑to‑market.
Risk Factors
Regulatory variability across regions, high capital intensity for facility expansion, and intense competition from established CDMOs.
Competitive Landscape
Competes with large CDMOs such as Catalent, Lonza, and Fujifilm Diosynth, differentiating through AI‑enabled automation and an integrated end‑to‑end service model.